Advanced in Psoriasis

Dr. Kathleen P. Flint

Rheumatology
Articularis Healthcare Group Inc
1711 Saint Julian Pl, 
Columbia, SC 
Accepting New Patients
43 Years of Experience
Advanced in Psoriasis
Articularis Healthcare Group Inc
1711 Saint Julian Pl, 
Columbia, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kathleen Flint is a Rheumatologist in Columbia, South Carolina. Dr. Flint has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Psoriasis. Her top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, and Eosinophilia-Myalgia Syndrome. Dr. Flint is currently accepting new patients.

Her clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Rheumatology
Licenses
Internal Medicine in SC
Hospital Affiliations
Prisma Health Tuomey Hospital
Kershawhealth
Prisma Health Richland Hospital
Lexington Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

ARTICULARIS HEALTHCARE GROUP INC
1711 Saint Julian Pl, Columbia, SC 29204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Advanced in Psoriasis
Dr. Robert E. Boyd
Rheumatology
Advanced in Psoriasis
Dr. Robert E. Boyd
Rheumatology

Arthritis Consultants PA

3 Richland Medical Park Dr, Suite 240, 
Columbia, SC 
 (2.1 miles away)
803-765-1550
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Boyd is a Rheumatologist in Columbia, South Carolina. Dr. Boyd is rated as an Advanced provider by MediFind in the treatment of Psoriasis. His top areas of expertise are Psoriatic Arthritis, Rheumatoid Arthritis (RA), Psoriasis, and Rheumatoid Vasculitis. Dr. Boyd is currently accepting new patients.

Advanced in Psoriasis
Dr. Bruce E. Goeckeritz
Rheumatology
Advanced in Psoriasis
Dr. Bruce E. Goeckeritz
Rheumatology
146 E Hospital Dr, Ste 550, 
West Columbia, SC 
 (6.4 miles away)
803-936-7410
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bruce Goeckeritz is a Rheumatologist in West Columbia, South Carolina. Dr. Goeckeritz is rated as a Distinguished provider by MediFind in the treatment of Psoriasis. His top areas of expertise are Rheumatoid Arthritis (RA), Juvenile Temporal Arteritis, Temporal Arteritis, and Giant Cell Arteritis (GCA). Dr. Goeckeritz is currently accepting new patients.

Advanced in Psoriasis
Dr. Adam D. Meszaros
Rheumatology
Advanced in Psoriasis
Dr. Adam D. Meszaros
Rheumatology

Arthritis Consultants PA

3 Richland Medical Park Dr, Suite 240, 
Columbia, SC 
 (2.1 miles away)
803-765-1550
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Adam Meszaros is a Rheumatologist in Columbia, South Carolina. Dr. Meszaros is rated as an Advanced provider by MediFind in the treatment of Psoriasis. His top areas of expertise are Psoriatic Arthritis, Rheumatoid Arthritis (RA), Psoriasis, and Rheumatoid Vasculitis. Dr. Meszaros is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Flint's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile